Vascarta Announces Completion of Phase 1 Clinical Trial of VAS-101 for the Treatment of Osteoarthritis

SUMMIT, N.J., Sept. 29, 2025 /PRNewswire/ -- Vascarta Inc., a clinical-stage biopharmaceutical company advancing innovative treatments for pain and inflammation, announced today the successful completion of its phase 1 clinical trial evaluating VAS-101 (Vasceptor®) for the treatment of...

Read More